Search
ChatPaper
AI Writing
analysis
Analysis
编组
Open Data
more
More
RankingsMust ReadingJournal&ConferenceAI TRAI HistoryMaster Reading TreeXiaomai's Star TalentsTrajectoryTalentNDI TrackerOpenAI sign Language
VIPCreated with Sketch.

Anti–programmed death ligand 1 immunotherapies in cancer patients with pre-existing systemic sclerosis: A postmarketed phase IV safety assessment study

Marion Panhaleux,Olivier Espitia,Benjamin Terrier,Guillaume Manson,Alexandre Maria,Sébastien Humbert,Benoît Godbert,Julie Perrin,Aurélie Achille,Jennifer Arrondeau,Marie Kostine,Vincent Fallet,Grégory Pugnet,Benjamin Chaigne,Stéphane Champiat,Ariane Laparra,Francois-Xavier Danlos,David Launay,Nicolas Penel,Olivier Lambotte,Jean-Marie Michot,Alexandra Forestier

European Journal of Cancer（2022）

Cited 10|Views11
No score
Abstract
•Immune checkpoint inhibitors can generate immune-related adverse events (irAEs).•IrAEs are more frequent in patients with pre-existing autoimmune diseases (AIDs).•Systemic Sclerosis (SSc) is an AID associated with cancer.•Anti-PD(L)1 immunotherapies are an acceptable anti-cancer treatment for SSc patients.
More
Translated text
Key words
Anti-PD-L1 immunotherapy,Anti-PD1 immunotherapy,Systemic sclerosis,Immune checkpoint inhibitor
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined